

# Xianghua Huang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2511428/publications.pdf>

Version: 2024-02-01

15  
papers

242  
citations

1478505

6  
h-index

1058476

14  
g-index

15  
all docs

15  
docs citations

15  
times ranked

316  
citing authors

#	ARTICLE	IF	CITATIONS
1	Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial. <i>BMC Medicine</i> , 2014, 12, 2.	5.5	69
2	The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 120-126.	2.9	46
3	Detection of Anti-PLA2R Autoantibodies and IgG Subclasses in Post-allogeneic Hematopoietic Stem Cell Transplantation Membranous Nephropathy. <i>American Journal of the Medical Sciences</i> , 2013, 346, 32-37.	1.1	38
4	Autologous Hematopoietic Stem Cell Transplantation for Refractory Lupus Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 719-727.	4.5	20
5	Utility of abdominal skin plus subcutaneous fat and rectal mucosal biopsy in the diagnosis of AL amyloidosis with renal involvement. <i>PLoS ONE</i> , 2017, 12, e0185078.	2.5	18
6	Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2016, 23, 51-57.	3.0	14
7	Dissecting the genotype-phenotype correlation of <i>COL4A5</i> gene mutation and its response to renin-angiotensin-aldosterone system blockers in Chinese male patients with Alport syndrome. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2487-2495.	0.7	8
8	A risk stratification for systemic immunoglobulin light chain amyloidosis with renal involvement. <i>British Journal of Haematology</i> , 2019, 187, 459-469.	2.5	7
9	The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 75-83.	3.0	7
10	Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation. <i>Medicine (United States)</i> , 2018, 97, e13589.	1.0	5
11	Combination of bortezomib in the induction, conditioning and consolidation with autologous hematopoietic stem cell transplantation in patients with immunoglobulin light chain amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, E101-E104.	4.1	4
12	The clinical features and outcomes of systemic light chain amyloidosis with hepatic involvement. <i>Annals of Medicine</i> , 2022, 54, 1226-1232.	3.8	3
13	Types of M protein and clinicopathological profiles in patients with monoclonal gammopathy of renal significance. <i>Journal of Nephrology</i> , 2020, 34, 1137-1146.	2.0	2
14	Using digital whole-slide images to evaluate renal amyloid deposition and its association with clinical features and outcomes of AL amyloidosis. <i>Journal of Nephrology</i> , 2021, 34, 1747-1756.	2.0	1
15	MO135: Efficacy and Safety of Bortezomib Combined with Autologous Stem Cell Transplantation in the Treatment of MGRS. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0